BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 10, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

RHB-101 regulatory update

RedHill said it plans to submit an NDA to FDA and an MAA to EMA no earlier than 2H14 for RHB-101 to treat congestive heart failure and hypertension after it met with FDA to discuss the compound's regulatory path. The company plans to conduct additional CMC...

Read the full 207 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >